Cancer is not one disease, it’s over 200, and each type is driven by distinct molecular mechanisms. This is why oncology drug discovery requires precision, flexibility and innovation.
We support innovative cancer therapies, from early discovery to clinical translation, by leveraging advanced technologies, collaborative partnerships and bespoke biomarker strategies.
We help our partners to address the toughest oncology challenges, from target identification and validation to mechanism of action studies, to evaluating clinical potential.
Whether you’re developing small molecules, complex biologics, or novel RNA-based therapies, our multidisciplinary expertise accelerates confident decision-making and reduces risk.
We help researchers navigate this complexity through a suite of advanced capabilities:
Target Validation
Confirm novel therapeutic targets using robust, disease-relevant models.
Exploration of New Modalities
Investigate novel therapeutic approaches aligned to specific cancer types.
Mechanistic insight and drug-disease interaction
Elucidate how therapies act in complex cancer systems using translational models and multi-omic profiling.
Clinical strategy and sample access
Shape clinical questions, define biomarker strategies, and access high-quality clinical samples for validation.
In vitro Oncology models
We evaluate mechanism of action and phenotypic responses in cellular models to validate targets and study drug mechanisms. Using high-content imaging, live-cell assays, and multi-omic profiling, we help to confirm drug-target engagement and build evidence of therapeutic potential, including immune modulation and tumour response.
In vivo efficacy and distribution
We provide expertise in selecting and running relevant murine models, CDX, PDX, and syngeneic systems. Our imaging platforms allow real-time monitoring of tumour growth, distribution, and response to therapy. These insights enable early detection of treatment effects and support the development of personalised strategies.
Ex vivo therapeutic validation
We apply advanced ex vivo analysis to investigate mechanistic insights, predict patient-specific responses, and explore novel treatment combinations. Using clinically relevant samples and models, our platforms enable phenotypic characterisation, immune profiling, and functional response evaluation. This approach bridges the gap between in vitro data and in vivo outcomes, supporting translational decisions in early drug development.
Biomarker and Clinical strategy
We specialise in biomarker-driven decision support to improve translational outcomes.
“We help to de-risk Oncology projects by building evidence that spans from Target Validation to Phenotypic Response. We bring the biology, tools and insight needed to support confident, translational decision-making.”
Dr Martin Main, Chief Scientific Officer
Our collaborative approach ensures every project is aligned with real-world clinical goals.
We work flexibly across small biotech, academia and pharma, offering access to our in-house platforms or integrated support through our expert partner network.
From advisory input to experimental execution, we are here to aid faster progress, with an even greater confidence.
Whether you need pre-clinical model guidance, biomarker strategy, or a full translational workflow, we are ready to support your next breakthrough.
